Axsome Therapeutics (AXSM) Return on Sales (2022 - 2026)

Axsome Therapeutics has disclosed Return on Sales across 5 years of filings, most recently posting 0.0% for Q1 2026.

• Return on Sales for Q1 2026 came in at 0.0%, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.0% (up 1.0% YoY), and the FY2025 annual result was 0.0%, changed 0.0% from the prior year.
• Return on Sales came in at 0.0% for Q1 2026 at Axsome Therapeutics, down from 0.0% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.0% in Q1 2023 to a low of 1.5% in Q4 2024.
• The 5-year median for Return on Sales is 0.01% (2024), against an average of 0.1%.
• Across the five-year window, Return on Sales slumped 148 bps in 2024 and soared 150 bps in 2025, its largest moves.
• Axsome Therapeutics' Return on Sales stood at 0.03% in 2022, then soared by 45 bps to 0.01% in 2023, then sank by 10763 bps to 1.5% in 2024, then jumped by 100 bps to 0.0% in 2025, then plunged by 131 bps to 0.0% in 2026.
• The last three Return on Sales figures came in at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.